TY - JOUR
T1 - Lymphoma of the Lacrimal Gland — An International Multicenter Retrospective Study
AU - Vest, Stine Dahl
AU - Mikkelsen, Lauge Hjorth
AU - Holm, Frederik
AU - Rasmussen, Peter Kristian
AU - Hindso, Tine Gadegaard
AU - Knudsen, Marina K.H.
AU - Coupland, Sarah E.
AU - Esmaeli, Bita
AU - Finger, Paul T.
AU - Graue, Gerardo F.
AU - Grossniklaus, Hans E.
AU - Honavar, Santosh G.
AU - Mulay, Kaustubh
AU - Sjö, Lene D.
AU - Sniegowski, Matthew C.
AU - Vemuganti, Geeta K.
AU - Thuro, Bradley A.
AU - Heegaard, Steffen
N1 - Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/11
Y1 - 2020/11
N2 - Purpose: To characterize the clinical features of subtype-specific lacrimal gland lymphoma and their effect on patient survival. Design: Multicenter retrospective interventional case series. Methods: Patient data were collected from 6 international eye cancer centers from January 1, 1980, through December 31, 2017. All patients with histologically verified primary or secondary lymphoma of the lacrimal gland were included. Primary endpoints were overall survival (OS) and disease-specific survival (DSS). Results: A total of 260 patients with lacrimal gland lymphoma were identified. The median age was 58 years and 52% of patients were men. Non-Hodgkin B-cell lymphomas constituted 99% (n = 258) and T-cell lymphomas constituted 1% (n = 2). The most frequent lymphoma subtypes were extranodal marginal zone B-cell lymphoma (EMZL) (n = 177, 68%), follicular lymphoma (FL) (n = 26, 10%), diffuse large B-cell lymphoma (DLBCL) (n = 25, 10%), and mantle cell lymphoma (MCL) (n = 17, 7%). Low-grade lymphomas (EMZL and FL) were most commonly treated with external beam radiotherapy (EBRT), whereas high-grade lymphomas (DLBCL and MCL) were treated with chemotherapy in combination with rituximab and/or EBRT. The prognosis was relatively good with a 5-year OS and DSS of 73.8% and 87.5%, respectively. Lymphoma subtype was a statistically significant predictor for DSS, with EMZL (5-year DSS: 93.4%) having the best prognosis and DLBCL (5-year DSS: 52.6%) having the poorest. Conclusions: This is the largest reported collection of data of subtype-specific lacrimal gland lymphoma. The subtype distribution of lacrimal gland lymphoma resembles that of the ocular adnexa. Prognosis is good and the histologic subtype is a significant predictor for disease-specific survival.
AB - Purpose: To characterize the clinical features of subtype-specific lacrimal gland lymphoma and their effect on patient survival. Design: Multicenter retrospective interventional case series. Methods: Patient data were collected from 6 international eye cancer centers from January 1, 1980, through December 31, 2017. All patients with histologically verified primary or secondary lymphoma of the lacrimal gland were included. Primary endpoints were overall survival (OS) and disease-specific survival (DSS). Results: A total of 260 patients with lacrimal gland lymphoma were identified. The median age was 58 years and 52% of patients were men. Non-Hodgkin B-cell lymphomas constituted 99% (n = 258) and T-cell lymphomas constituted 1% (n = 2). The most frequent lymphoma subtypes were extranodal marginal zone B-cell lymphoma (EMZL) (n = 177, 68%), follicular lymphoma (FL) (n = 26, 10%), diffuse large B-cell lymphoma (DLBCL) (n = 25, 10%), and mantle cell lymphoma (MCL) (n = 17, 7%). Low-grade lymphomas (EMZL and FL) were most commonly treated with external beam radiotherapy (EBRT), whereas high-grade lymphomas (DLBCL and MCL) were treated with chemotherapy in combination with rituximab and/or EBRT. The prognosis was relatively good with a 5-year OS and DSS of 73.8% and 87.5%, respectively. Lymphoma subtype was a statistically significant predictor for DSS, with EMZL (5-year DSS: 93.4%) having the best prognosis and DLBCL (5-year DSS: 52.6%) having the poorest. Conclusions: This is the largest reported collection of data of subtype-specific lacrimal gland lymphoma. The subtype distribution of lacrimal gland lymphoma resembles that of the ocular adnexa. Prognosis is good and the histologic subtype is a significant predictor for disease-specific survival.
UR - http://www.scopus.com/inward/record.url?scp=85090209601&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090209601&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2020.06.015
DO - 10.1016/j.ajo.2020.06.015
M3 - Article
C2 - 32574779
AN - SCOPUS:85090209601
SN - 0002-9394
VL - 219
SP - 107
EP - 120
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
ER -